TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06770881: Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 430 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06770881 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06770881 Rescue Dossier →